^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ETH-155008

    i
    Other names: ETH-155008, ETH 155008, Euthare-155008
    Associations

    News

    Trials
    Company:
    Shengke Pharmaceuticals
    Drug class:
    PIM-1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    8ms
    A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients (clinicaltrials.gov)
    P1, N=60, Recruiting, Shengke Pharmaceuticals (Jiangsu) Limited, China | Trial completion date: Mar 2025 --> Jun 2026 | Trial primary completion date: Feb 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    ETH-155008
    1year
    First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML (clinicaltrials.gov)
    P1a/1b, N=9, Terminated, Shengke Pharmaceuticals Pty Ltd | N=67 --> 9 | Recruiting --> Terminated; The reasons for early termination is due to slow recruitment
    Enrollment change • Trial termination
    |
    FLT3 (Fms-related tyrosine kinase 3) • RB1 (RB Transcriptional Corepressor 1)
    |
    RB1 positive
    |
    ETH-155008
    almost2years
    A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients (clinicaltrials.gov)
    P1, N=60, Recruiting, Shengke Pharmaceuticals (Jiangsu) Limited, China
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • CDK4 (Cyclin-dependent kinase 4)
    |
    ETH-155008
    almost2years
    First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML (clinicaltrials.gov)
    P1a/1b, N=67, Recruiting, Shengke Pharmaceuticals Pty Ltd | Active, not recruiting --> Recruiting
    Enrollment open
    |
    FLT3 (Fms-related tyrosine kinase 3) • RB1 (RB Transcriptional Corepressor 1)
    |
    RB1 positive
    |
    ETH-155008
    almost2years
    First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML (clinicaltrials.gov)
    P1a/1b, N=9, Active, not recruiting, Shengke Pharmaceuticals Pty Ltd | Recruiting --> Active, not recruiting | N=67 --> 9
    Enrollment closed • Enrollment change
    |
    FLT3 (Fms-related tyrosine kinase 3) • RB1 (RB Transcriptional Corepressor 1)
    |
    RB1 positive
    |
    ETH-155008
    over3years
    First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML (clinicaltrials.gov)
    P1a/1b, N=67, Recruiting, Shengke Pharmaceuticals Pty Ltd | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    FLT3 (Fms-related tyrosine kinase 3) • RB1 (RB Transcriptional Corepressor 1)
    |
    RB1 positive
    |
    ETH-155008